I. Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.
Metabolic Liver Research Programme, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany.
United European Gastroenterol J. 2020 Oct;8(8):942-948. doi: 10.1177/2050640620944098. Epub 2020 Jul 23.
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. Its role in the development of extrahepatic co-morbidities is under investigation. The impact of NAFLD on the development of chronic kidney disease (CKD) is incompletely understood. The aim of this study was to explore the potential contribution of NAFLD on CKD in Germany.
The Disease Analyzer Database covering 7.49 million cases in Germany was explored for patients diagnosed with NAFLD between 2000 and 2015 and was matched 1:1 to a cohort without NAFLD. Matching criteria included age, sex, physician, index year and co-diagnoses associated with CKD. The primary outcomes of this study were incidences of CKD and end-stage renal disease.
A total of 48,057 patients with NAFLD were matched to 48,057 patients without NAFLD. Within 10 years of the index date, 17.1% of patients with NAFLD and 11.6% of patients without NAFLD were diagnosed with CKD ( < 0.001). On Cox regression analysis, NAFLD was significantly associated with the incidence of CKD (hazard ratio (HR) = 1.58, < 0.001). This association remained significant across different age groups and subgroups such as patients with diabetes mellitus or arterial hypertension. There was no association between NAFLD and emerging dialysis therapy (HR = 1.25, = 0.245).
In this large database analysis in Germany, NAFLD constitutes an independent risk factor for CKD. Patients living with NAFLD should be monitored for a change in kidney function, facilitating therapeutic measures for kidney disease at an early stage.
非酒精性脂肪性肝病(NAFLD)是一种高发的慢性肝病。其在肝外合并症发展中的作用仍在研究中。NAFLD 对慢性肾脏病(CKD)发展的影响尚未完全明确。本研究旨在探讨 NAFLD 在德国对 CKD 的潜在影响。
对德国覆盖 749 万例患者的疾病分析数据库进行了研究,共纳入 2000 年至 2015 年间诊断为 NAFLD 的患者,并与无 NAFLD 的患者进行 1:1 匹配。匹配标准包括年龄、性别、医生、索引年和与 CKD 相关的合并症。本研究的主要结局是 CKD 和终末期肾病的发生率。
共纳入 48057 例 NAFLD 患者和 48057 例无 NAFLD 患者。在索引日期后的 10 年内,17.1%的 NAFLD 患者和 11.6%的无 NAFLD 患者被诊断为 CKD(<0.001)。在 Cox 回归分析中,NAFLD 与 CKD 的发生显著相关(风险比[HR] = 1.58,<0.001)。这种相关性在不同年龄组和亚组(如患有糖尿病或动脉高血压的患者)中仍然显著。NAFLD 与新兴透析治疗之间无相关性(HR = 1.25,=0.245)。
在这项德国的大型数据库分析中,NAFLD 是 CKD 的独立危险因素。患有 NAFLD 的患者应监测肾功能变化,以便及早采取治疗措施防治肾脏疾病。